Research Paper Volume 12, Issue 24 pp 26063—26079
An Immuno-Clinic score model for evaluating T cell immunity and predicting early antiviral therapy effectiveness in chronic hepatitis B
Figure 1. Expression of three pairs of antiviral cytokines and five pairs of inhibitory molecules by CD4+ and CD8+ T cells from naïve CHB patients. (A) Expression of antiviral cytokines IFN-γ, TNF-α, and IL-2 by CD4+ and CD8+ T cells derived from the indicated patient groups. The levels were compared among patients in the IT, IA, GZ, IC phases and healthy controls. (B) Expression of inhibitory molecules PD-1, Tim-3, LAG-3, CTLA4, and 2B4 were measured on CD4+ and CD8+ T cells derived from the indicated patient groups. The levels were compared among patients in the IT, IA, GZ, IC phases and healthy controls. Differences between multiple groups were evaluated by the Wilcoxon rank sum test. Data is presented as the median (indicated by a red line). *P < 0.05.